Back to Search Start Over

Neuroimaging and clinical outcomes of oral anticoagulant–associated intracerebral hemorrhage

Authors :
Tsivgoulis, G. Wilson, D. Katsanos, A.H. Sargento-Freitas, J. Marques-Matos, C. Azevedo, E. Adachi, T. von der Brelie, C. Aizawa, Y. Abe, H. Tomita, H. Okumura, K. Hagii, J. Seiffge, D.J. Lioutas, V.-A. Traenka, C. Varelas, P. Basir, G. Krogias, C. Purrucker, J.C. Sharma, V.K. Rizos, T. Mikulik, R. Sobowale, O.A. Barlinn, K. Sallinen, H. Goyal, N. Yeh, S.-J. Karapanayiotides, T. Wu, T.Y. Vadikolias, K. Ferrigno, M. Hadjigeorgiou, G. Houben, R. Giannopoulos, S. Schreuder, F.H.B.M. Chang, J.J. Perry, L.A. Mehdorn, M. Marto, J.-P. Pinho, J. Tanaka, J. Boulanger, M. Salman, R.A.-S. Jäger, H.R. Shakeshaft, C. Yakushiji, Y. Choi, P.M.C. Staals, J. Cordonnier, C. Jeng, J.-S. Veltkamp, R. Dowlatshahi, D. Engelter, S.T. Parry-Jones, A.R. Meretoja, A. Mitsias, P.D. Alexandrov, A.V. Ambler, G. Werring, D.J.
Publication Year :
2018

Abstract

Objective: Whether intracerebral hemorrhage (ICH) associated with non–vitamin K antagonist oral anticoagulants (NOAC-ICH) has a better outcome compared to ICH associated with vitamin K antagonists (VKA-ICH) is uncertain. Methods: We performed a systematic review and individual patient data meta-analysis of cohort studies comparing clinical and radiological outcomes between NOAC-ICH and VKA-ICH patients. The primary outcome measure was 30-day all-cause mortality. All outcomes were assessed in multivariate regression analyses adjusted for age, sex, ICH location, and intraventricular hemorrhage extension. Results: We included 7 eligible studies comprising 219 NOAC-ICH and 831 VKA-ICH patients (mean age = 77 years, 52.5% females). The 30-day mortality was similar between NOAC-ICH and VKA-ICH (24.3% vs 26.5%; hazard ratio = 0.94, 95% confidence interval [CI] = 0.67–1.31). However, in multivariate analyses adjusting for potential confounders, NOAC-ICH was associated with lower admission National Institutes of Health Stroke Scale (NIHSS) score (linear regression coefficient = −2.83, 95% CI = −5.28 to −0.38), lower likelihood of severe stroke (NIHSS > 10 points) on admission (odds ratio [OR] = 0.50, 95% CI = 0.30–0.84), and smaller baseline hematoma volume (linear regression coefficient = −0.24, 95% CI = −0.47 to −0.16). The two groups did not differ in the likelihood of baseline hematoma volume < 30cm3 (OR = 1.14, 95% CI = 0.81–1.62), hematoma expansion (OR = 0.97, 95% CI = 0.63–1.48), in-hospital mortality (OR = 0.73, 95% CI = 0.49–1.11), functional status at discharge (common OR = 0.78, 95% CI = 0.57–1.07), or functional status at 3 months (common OR = 1.03, 95% CI = 0.75–1.43). Interpretation: Although functional outcome at discharge, 1 month, or 3 months was comparable after NOAC-ICH and VKA-ICH, patients with NOAC-ICH had smaller baseline hematoma volumes and less severe acute stroke syndromes. Ann Neurol 2018;84:702–712. © 2018 American Neurological Association

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.od......2127..efe06c4c781cd9c60a4dee3322ed1143